140 related articles for article (PubMed ID: 7756183)
21. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
[TBL] [Abstract][Full Text] [Related]
22. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
23. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.
Jäger M; Riedel M; Schmauss M; Pfeiffer H; Laux G; Naber D; Gaebel W; Huff W; Schmidt LG; Heuser I; Buchkremer G; Kühn KU; Rüther E; Hoff P; Gastpar M; Bottlender R; Strauss A; Möller HJ
Psychiatry Res; 2008 Apr; 158(3):297-305. PubMed ID: 18280582
[TBL] [Abstract][Full Text] [Related]
24. [Clinical effects of clozapine: effect on negative symptoms].
Llorca PM; Lançon C; Auquier P; Bougerol T
Encephale; 1996; 22(4):287-92. PubMed ID: 9035984
[TBL] [Abstract][Full Text] [Related]
25. The psychopathology of schizophrenia: an integrated view on positive symptoms and negative symptoms.
Möller HJ
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():57-64. PubMed ID: 8866766
[TBL] [Abstract][Full Text] [Related]
26. Depression in patients with schizophrenia during an acute psychotic episode.
Tapp A; Kilzieh N; Wood AE; Raskind M; Tandon R
Compr Psychiatry; 2001; 42(4):314-8. PubMed ID: 11458306
[TBL] [Abstract][Full Text] [Related]
27. [Schizophrenia and violence, incidence and risk factors: a Tunisian sample].
Ellouze F; Ayedi S; Masmoudi S; Bakri L; Chérif W; Zramdini R; Largueche M; Amri H; Ben Abla T; M'rad MF
Encephale; 2009 Sep; 35(4):347-52. PubMed ID: 19748371
[TBL] [Abstract][Full Text] [Related]
28. [Atypical neuroleptics--the future of schizophrenia treatment?].
Ebert D
Fortschr Med; 1998 Jan; 116(3):22-8. PubMed ID: 9522541
[TBL] [Abstract][Full Text] [Related]
29. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
30. Aspects of clinical psychiatric research on depot neuroleptics. The presentation of two double-blind trials with cis(z)-clopenthixol decanoate and a withdrawal study in schizophrenics.
Dencker SJ; Elgen K
Acta Psychiatr Scand Suppl; 1980; 279():5-9. PubMed ID: 6996425
[No Abstract] [Full Text] [Related]
31. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
32. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
[TBL] [Abstract][Full Text] [Related]
33. [Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms].
Petit M; Langlois S
Encephale; 1996 Jun; 22 Spec No 2():13-8. PubMed ID: 8767036
[TBL] [Abstract][Full Text] [Related]
34. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
35. [cis(Z)-Clopenthixol decanoate--a new depot neuroleptic].
Sieberns S; Spechtmeyer H
Int Pharmacopsychiatry; 1982; 17(3):170-84. PubMed ID: 7141812
[TBL] [Abstract][Full Text] [Related]
36. Schizophrenic relapse after drug withdrawal is predictable.
Dencker SJ; Malm U; Lepp M
Acta Psychiatr Scand; 1986 Feb; 73(2):181-5. PubMed ID: 3705994
[TBL] [Abstract][Full Text] [Related]
37. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
Molero P; Ortuño F; Zalacain M; Patiño-García A
Pharmacogenomics J; 2007 Dec; 7(6):418-26. PubMed ID: 17363961
[TBL] [Abstract][Full Text] [Related]
38. Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot.
Dom R; De Mesmaecker L; van den Broucke M; van Hest T; Baro F
Acta Psychiatr Scand; 1978 Apr; 57(4):299-304. PubMed ID: 352094
[TBL] [Abstract][Full Text] [Related]
39. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
40. [Monitored supportive treatment of chronic schizophrenia with delayed-action clopenthixol].
Welbel L; Nurowska K; Szukalski B; Lipska B
Psychiatr Pol; 1985; 19(2):109-14. PubMed ID: 4095213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
